C

Carmell Corp
NASDAQ:CTCX

Watchlist Manager
Carmell Corp
NASDAQ:CTCX
Watchlist
Price: 0.1973 USD 1.39% Market Closed
Market Cap: 5.9m USD

Operating Margin
Carmell Corp

-28 075.9%
Current
-2 413%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-28 075.9%
=
Operating Profit
-9.2m
/
Revenue
32.8k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Carmell Corp
NASDAQ:CTCX
5.9m USD
-28 076%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
330.5B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
128.5B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Carmell Corp
Glance View

Market Cap
5.9m USD
Industry
Biotechnology

Carmell Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 10 full-time employees. The company went IPO on 2021-07-29. Carmell Corporation, formerly Carmell Therapeutics Corporation, is a regenerative medicine platform company. The firm is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. Its lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing its core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.

CTCX Intrinsic Value
0.0516 USD
Overvaluation 74%
Intrinsic Value
Price
C
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-28 075.9%
=
Operating Profit
-9.2m
/
Revenue
32.8k
What is the Operating Margin of Carmell Corp?

Based on Carmell Corp's most recent financial statements, the company has Operating Margin of -28 075.9%.

Back to Top